Dosing begins in first-in-human study of CAN-106 for complement dysregulation diseases March 10, 2021
FDA accepts IND application for EP-7041 for thrombosis prevention in patients with COVID-19 March 4, 2021
Enrollment completed in phase II study of SSS-06 long-acting erythropoietin-stimulating protein Feb. 25, 2021
Enrollment ongoing in phase III study of LNP-023 in adults with PNH with residual anemia Feb. 11, 2021
RSS